Hikal Ltd., a preferred long-term partner for leading global life sciences companies, today announced that they have signed a multi-year contract with a leading global pharmaceutical company. This contract entails the development and supply of a portfolio of niche APIs over a period of 10 years. The development will start this year and commercial supplies will commence post successful development and plant commercialization estimated to be in FY 2024 onwards. With this deal, Hikal is entering into a niche area of chemistry and products thereby bolstering its Animal Health vertical. Hikal and its customer will be jointly investing at its Panoli, Gujarat site to set up a multipurpose manufacturing asset for the manufacturing of these API.
Commenting on this development, Mr. Sameer Hiremath, CEO, Hikal said, “We are very excited to be working with one of the leading global innovator pharmaceutical companies who have entrusted us to supply them with a strategic portfolio of APIs. We worked very closely with our customer to provide them a sustainable long-term competitive solution for their product portfolio from early-stage development to commercial supply. Hikal and our customer will be partnering in setting up a manufacturing facility to maintain the security of supplies for the next ten years. We are seeing multiple opportunities from several new and existing customers who are looking to diversify and de-risk their existing supply chain.”
The content is a Press Release. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or quality of the content.